Biochemistry Research International · 5 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review summarizes evidence from preclinical and clinical studies on the potential role of Coenzyme Q10 (CoQ10) in various neurodegenerative and psychiatric diseases. The central finding is that while animal and mechanistic studies often suggest neuroprotective benefits, human clinical trial results for CoQ10 in specific conditions like Parkinson's and Huntington's disease have generally not shown a clear, statistically significant therapeutic benefit.
This narrative review discusses the biology of Coenzyme Q10 (CoQ10) and summarizes research on its potential therapeutic role in neurodegenerative and psychiatric disorders, including Parkinson's disease, Alzheimer's disease, Huntington's disease, and depression. However, it reports that human clinical trial evidence is mixed and often inconclusive. For instance, in Parkinson's disease, meta-analyses indicate CoQ10 is well-tolerated but not superior to placebo for motor symptoms. Similarly, a large trial in Huntington's disease found no beneficial effect. The review also notes lower CoQ10 levels in patients with several conditions, suggesting a potential link.
